« The majority of patients with Bcr-Abl negative myeloproliferative neoplasms (MPN) have a JAK2-V617F mutation. Targeted therapy with JAK-inhibitors have been shown to normalize blood parameters but do not lead to a significant reduction in the mutant allelic burden. Interferon-alpha (IFNα) therapy is the only treatment option available that can achieve molecular remission. However, long-term treatment with IFNα is required and patients frequently exhibit adverse side-effects. Thus it is important to elucidate the mechanism of action of IFNα in achieving molecular remission, which is still not completely understood. Previous studies in JAK2-mutant MPN mouse model have shown that IFNα treatment leads to the depletion of the mutant hematopoietic stem cells (HSCs). Our previous findings have shown that IFNα can drive wildtype dormant HSCs into cell cycle, leading to attrition of functional HSCs. We hypothesize that IFNα treatment eliminates the functional disease-propagating JAK2-mutant HSCs by breaking their dormant status
. »